INTERVENTIONAL RADIOLOGY

Transforming cryoablation cancer treatment with ProSense™

NEW CLINICAL RESULTS

Published results in Israel treating recurrent kidney tumors after primary nephron-sparing surgery demonstrated a 100% oncologic success in 7 patients. No tumors showed contrast enhancement or growth on follow-up imaging.

CLINICAL PROGRESS

IceCure is currently establishing strong clinical foundations in interventional oncology to enable ProSense™ treatment for cancer of the kidney, lung, bone, and prostate.

Clinical trials treating lung and kidney cancer percutaneously under CT with ProSense™ cryoablation are indicating exceptional outcomes in Japan and Israel.

wisconsin

new york

tennessee

california

mexico

colombia

New Mexico

italy

South Africa

japan

hong kong

thailand

Singapore

Germany

Spain

Hungary

Israel

France

Australia

India

China

Romania

Michigan

Costa Rica

“I have been using the ProSense^TM system for all my cryoablation procedures for the past year. I have plenty of experience using the typical argon-based systems – and IceCure offers several advantages over those systems. First, the rate of freeze is much faster. We know from studies this is important to enhance the anti-cancer immune response from cryoablation. Second, the cost per procedure is less, not only because you can achieve larger ablation zones with a single needle, but also because liquid nitrogen is less expensive than gases needed for the other systems. I feel that the fast freezing and consistent ablation provided by the ProSense^TM system is essential to our work in generating a systemic immune response combining cryoablation with the injection of immunotherapy.”

Jason R. Williams, MD
Director of Interventional Oncology,
Williams Cancer Institute,
Atlanta, GA and Mexico City, Mexico

CLINICAL SUPPORT

Clinical studies with ProSense™ are currently underway at centers of excellence worldwide.

ProSense™ Treatment of Lung Cancer
Ongoing independent trial, Japan

Lead investigator
Dr. Hiroaki Nomori, M.D., Ph.D., Chairman of the Department of General Thoracic Surgery, Kameda Medical Center, Japan

Early evaluation
Over 250 patients treated with ProSense™ to date
Three-year follow-up on ~30 T1mi +T1a +T1b cancer patients (<2cm mass) shows overall survival rate of 100% after ProSense™ therapy vs. ~78% after radiation therapy. [1]

References:

[1] Hiraki T. Lung Radiofrequency Ablation: Educational Lectures (EL2-1); Cryomedicine 2017: The 44th Annual Meeting of the Japanese Society for Low Temperature Medicine.

[2] Shprits S. et al., 2019 Cryoablation for recurrent renal tumors after primary nephron-sparing surgery using an innovative liquid nitrogen-based cryogenic device.
Journal of Molecular and Clinical Medicine: 2 (1):11-14.

ProSense™ Treatment of Renal Cancer
Ongoing trial and collaborative clinical research, Israel

Lead investigators
Prof. Ofer Nativ, Head of the Urological Department, Bnai Zion Medical Center, Israel
Dr. Robert Sachner, Head of Interventional Radiology, Bnai Zion Medical Center, Israel

Published results
Of 7 patients with tumor recurrence after nephron-sparing surgery, none of the treated tumor lesions demonstrated contrast enhancement or growth on follow up imaging indicating a 100% oncologic success. Only three adverse events were recorded. Investigators found cryoablation with the ProSense™ system is feasible and effective, with excellent renal function preservation and without major complications. [2]

Read the published results >

Early evaluation
Of 74 patients with 78 small kidney masses (≤ 4cm) treated, ProSense™ showed treatment success by lack of enhancement on CT or MRI in 93% (42 of 45) of cases at 1 year follow-up. Investigators found the ProSense™ system to be safe, effective and without serious adverse events.

View the full poster >